Acelrx Pharmaceuticals Incのボラティリティ
Acelrx Pharmaceuticals Incのボラティリティは何ですか。
Acelrx Pharmaceuticals Incのボラティリティは11.23%です。
ボラティリティの定義は何ですか。
ボラティリティまたは平均真の範囲パーセント（ATRP14）は、終値のパーセンテージとして表されるATRです。
Average true range percent (ATRP) measures volatility on a relative level. This is opposed to the ATR, which measures volatility on an absolute level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks won't necessarily have lower ATR values than higher-priced stocks.
The period used in the calculation is 14 days and the normalized indicator oscillates between 0 and 100 percent of recent price variation. Importantly, the indicator doesn't predict the direction of price but it describes the current volatility. The volatility is comparable across all securities and all markets.
Volatility expresses the degree of price movement. The use of ATRP as volatility compared to ATR is preferred in cases when different securities or different time periods are compared. Examples are stock screening, filtering strategies, and studying seasonality and volatility patterns over long periods of time and different markets
NASDAQのセクタHealth Careにおけるボラティリティの企業と比べるAcelrx Pharmaceuticals Inc
Acelrx Pharmaceuticals Incは何をしますか。
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Acelrx Pharmaceuticals Incと類似のボラティリティ
- WestKam Goldのボラティリティは11.20%です。
- Easymotionskin Tec Sf ,1のボラティリティは11.21%です。
- Baofeng Modern Internationalのボラティリティは11.21%です。
- First Responder Technologiesのボラティリティは11.21%です。
- Windwardのボラティリティは11.21%です。
- Ventoux CCM Acquisitionのボラティリティは11.22%です。
- Acelrx Pharmaceuticals Incのボラティリティは11.23%です。
- KOPR Point Venturesのボラティリティは11.24%です。
- Plantify Foods Incのボラティリティは11.24%です。
- Pacific Coast Oil Trustのボラティリティは11.24%です。
- Alien Metalsのボラティリティは11.25%です。
- GB Plcのボラティリティは11.25%です。
- Cytocom Incのボラティリティは11.25%です。